The decline comes as Tesla faces increased competition, particularly in China, and an aging vehicle lineup. To stimulate sales, Tesla has offered various discounts and incentives, such as zero-interest loans for Model 3 and Model Y purchases in China.
Inflation progress
Powell said the central bank had made “quite a bit of progress” on inflation over the past year but said he wants to see more before being confident enough to start cutting interest rates. “The last [inflation] reading and the one before it to a lesser extent, suggest that we are getting back on the disinflationary path,” Powell said at a central banking forum in Sintra, Portugal. “We want to be more confident that inflation is moving sustainably down toward 2% before we start the process of reducing or loosening policy.”
Alzheimer drug approval
The FDA has approved Eli Lilly’s Alzheimer’s drug, donanemab, expanding treatment options for the nearly 7 million Americans with the disease. Eli Lilly has faced obstacles in its path to market. The FDA rejected the drug’s approval last year due to insufficient data, then surprisingly delayed it again in March. Donanemab will now compete with Biogen and Japanese partner Eisai’s Leqembi, which gained approval last year.
Paramount bid?
Shares of Paramount Global popped 9% in extended trading after news of a potential deal between David Ellison’s Skydance and National Amusements, Paramount’s controlling shareholder. This preliminary agreement could give Skydance control of Paramount, marking a revival of a previously failed deal. While specific terms remain unclear, the previous deal involved a $2 billion payout to National Amusement’s controlling shareholder Shari Redstone, $4.5 billion for Paramount’s controlling shares and $1.5 billion cash for Paramount’s balance sheet.
areecep OP : Well, Lazard’s chief strategist Ronald Temple expects the Fed to cut rates three times by the end of this year — that’s more than the market is currently factoring in.